The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Open accessAbstract
The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, formerly AERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Besides those from manufacturers, reports can be submitted from health care professionals and the public. The original system was started in 1969, but since the last major revision in 1997, reporting has markedly increased. Data mining algorithms have been developed for the quantitative detection of signals from such a large database, where a signal means a statistical association between a drug and an adverse event or a drug-associated adverse event, including the proportional reporting ratio (PRR), the reporting odds ratio (ROR), the information component (IC), and the empirical Bayes geometric mean (EBGM). A survey of our previous reports suggested that the ROR provided the highest number of signals, and the EBGM the lowest. Additionally, an analysis of warfarin-, aspirin- and clopidogrel-associated adverse events suggested that all EBGM-based signals were included in the PRR-based signals, and also in the IC- or ROR-based ones, and that the PRR- and IC-based signals were in the ROR-based ones. In this article, the latest information on this area is summarized for future pharmacoepidemiological studies and/or pharmacovigilance analyses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Under-Reporting of Adverse Drug Reactions: A Systematic Review
Hazell, L., & Shakir, S. A. W. (2006) · Drug Safety · doi:10.2165/00002018-200629050-00003 · Cited by 1,931
Evans, S. J. W., Waller, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,802
A Bayesian neural network method for adverse drug reaction signal generation
Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., & De Freitas, R. M. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050466 · Cited by 1,476
van Puijenbroek, E. P., Bate, A., Leufkens, H. G. M., Lindquist, M., Orre, R., & Egberts, A. C. G. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.668 · Cited by 1,372
The reporting odds ratio and its advantages over the proportional reporting ratio
Rothman, K. J., Lanes, S., & Sacks, S. T. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1001 · Cited by 1,111
Quantitative signal detection using spontaneous ADR reporting
Bate, A., & Evans, S. J. W. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1742 · Cited by 912
Szarfman, A., Machado, S. G., & O??Neill, R. T. (2002) · Drug Safety · doi:10.2165/00002018-200225060-00001 · Cited by 700
VigiBase, the WHO Global ICSR Database System: Basic Facts
Lindquist, M. (2008) · Drug Information Journal · doi:10.1177/009286150804200501 · Cited by 587
Determinants of Under-Reporting of Adverse Drug Reactions: A Systematic Review
Lopez-Gonzalez, E., Herdeiro, M. T., & Figueiras, A. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00002 · Cited by 574
Montastruc, J., Sommet, A., Bagheri, H., & Lapeyre‐Mestre, M. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04037.x · Cited by 517
Wysowski, D. K., & Swartz, L. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1363 · Cited by 471
Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005
Moore, T. J. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.16.1752 · Cited by 462
Update on adverse drug events associated with parenteral iron
Chertow, G. M., Mason, P. D., Vaage-Nilsen, O., & Ahlmén, J. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi253 · Cited by 457
Pharmacovigilance: methods, recent developments and future perspectives
Härmark, L., & van Grootheest, A. C. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0475-9 · Cited by 289
Pariente, A., Gregoire, F., Fourrier-Reglat, A., Haramburu, F., & Moore, N. (2007) · Drug Safety · doi:10.2165/00002018-200730100-00007 · Cited by 268
Novel Statistical Tools for Monitoring the Safety of Marketed Drugs
Almenoff, J. S., Pattishall, E. N., Gibbs, T. G., DuMouchel, W., Evans, S. J. W., & Yuen, N. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100258 · Cited by 266
Perspectives on the Use of Data Mining in Pharmacovigilance
Almenoff, J., Tonning, J. M., Gould, A. L., Szarfman, A., Hauben, M., Ouellet-Hellstrom, R., Ball, R., Hornbuckle, K., Walsh, L., Yee, C., et al. (2005) · Drug Safety · doi:10.2165/00002018-200528110-00002 · Cited by 250
Piccinni, C., Motola, D., Marchesini, G., & Poluzzi, E. (2011) · Diabetes Care · doi:10.2337/dc10-2412 · Cited by 239
Lindquist, M., St??hl, M., Bate, A., Edwards, I. R., & Meyboom, R. H. B. (2000) · Drug Safety · doi:10.2165/00002018-200023060-00004 · Cited by 230
Figueiras, A., Herdeiro, M. T., Polónia, J., & Gestal-Otero, J. J. (2006) · JAMA · doi:10.1001/jama.296.9.1086 · Cited by 204
Hartnell, N. R., & Wilson, J. P. (2004) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.8.743.36068 · Cited by 172
Mining multi-item drug adverse effect associations in spontaneous reporting systems
Harpaz, R., Chase, H. S., & Friedman, C. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-s9-s7 · Cited by 171
Hauben, M., & Aronson, J. K. (2009) · Drug Safety · doi:10.2165/00002018-200932020-00003 · Cited by 170
The role of databases in drug postmarketing surveillance
Rodriguez, E. M., Staffa, J. A., & Graham, D. J. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.615 · Cited by 165
Decision support methods for the detection of adverse events in post-marketing data
Hauben, M., & Bate, A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.12.012 · Cited by 163
Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents
Lee, C., Gianos, M., & Klaustermeyer, W. B. (2009) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)60078-6 · Cited by 161
Practical pharmacovigilance analysis strategies
Gould, A. L. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.771 · Cited by 154
On the relative safety of parenteral iron formulations
Chertow, G. M., Mason, P. D., Vaage-Nilsen, O., & Ahlmén, J. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh185 · Cited by 149
Poluzzi, E., Raschi, E., Moretti, U., & Ponti, F. D. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1746 · Cited by 138
Physician Response to Patient Reports of Adverse Drug Effects
Golomb, B. A., McGraw, J. J., Evans, M. A., & Dimsdale, J. E. (2007) · Drug Safety · doi:10.2165/00002018-200730080-00003 · Cited by 131
Raschi, E., Piccinni, C. P., Poluzzi, E., Marchesini, G., & Ponti, F. D. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0340-7 · Cited by 126
Antimicrobials and the Risk of Torsades de Pointes
Poluzzi, E., Raschi, E., Motola, D., Moretti, U., & Ponti, F. D. (2010) · Drug Safety · doi:10.2165/11531850-000000000-00000 · Cited by 123
Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods
Montastruc, J., Sommet, A., Lacroix, I., Olivier, P., Durrieu, G., Damase‐Michel, C., Lapeyre‐Mestre, M., & Bagheri, H. (2006) · Joint Bone Spine · doi:10.1016/j.jbspin.2006.09.002 · Cited by 123
Effects of Statins on Skeletal Muscle: A Perspective for Physical Therapists
Stasi, S. L. D., MacLeod, T. D., Winters, J. D., & Binder‐Macleod, S. A. (2010) · Physical Therapy · doi:10.2522/ptj.20090251 · Cited by 119
Use of parenteral iron products and serious anaphylactic‐type reactions
Wysowski, D. K., Swartz, L., Borders‐Hemphill, V., Goulding, M. R., & Dormitzer, C. M. (2010) · American Journal of Hematology · doi:10.1002/ajh.21794 · Cited by 118
OpenVigil—free eyeballs on AERS pharmacovigilance data
Böhm, R., Höcker, J., Cascorbi, I., & Herdegen, T. (2012) · Nature Biotechnology · doi:10.1038/nbt.2113 · Cited by 114
Kadoyama, K., Kuwahara, A., Yamamori, M., Brown, J. B., Sakaeda, T., & Okuno, Y. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-93 · Cited by 90
Self-citationEvidence-Based Management of Statin Myopathy
Harper, C. R., & Jacobson, T. A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0120-9 · Cited by 79
Bailie, G. R. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110262 · Cited by 79
Biclustering of Adverse Drug Events in the FDA's Spontaneous Reporting System
Harpaz, R., Perez, H. R., Chase, H. S., Rabadán, R., Hripcsak, G. M., & Friedman, C. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.285 · Cited by 78
Data Quality Management in Pharmacovigilance
Lindquist, M. (2004) · Drug Safety · doi:10.2165/00002018-200427120-00003 · Cited by 77
Kadoyama, K., Miki, I., Tamura, T., Brown, J. B., Sakaeda, T., & Okuno, Y. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.9.33 · Cited by 75
Self-citationHerdeiro, M. T., Polónia, J. J., Gestal, J. J., & Figueiras, A. (2008) · Drug Safety · doi:10.2165/00002018-200831040-00007 · Cited by 74
Sakaeda, T., Kadoyama, K., & Okuno, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028124 · Cited by 74
Self-citationGavaza, P., Brown, C. M., Lawson, K. A., Rascati, K. L., Wilson, J. P., & Steinhardt, M. A. (2010) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2010.09.001 · Cited by 72
An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database
Wang, H., Hochberg, A. M., Pearson, R. K., & Hauben, M. (2010) · Drug Safety · doi:10.2165/11584390-000000000-00000 · Cited by 71
Influence of the MedDRA® hierarchy on pharmacovigilance data mining results
Pearson, R. K., Hauben, M., Goldsmith, D. I., Gould, A. L., Madigan, D., O’Hara, D. J., Reisinger, S. J., & Hochberg, A. M. (2009) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2009.01.001 · Cited by 70
A potential competition bias in the detection of safety signals from spontaneous reporting databases
Pariente, A., Didailler, M., Avillach, P., Miremont‐Salamé, G., Fourrier‐Réglat, A., Haramburu, F., & Moore, N. D. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2022 · Cited by 67
The FDA Drug Safety Surveillance Program: Adverse Event Reporting Trends
Smith, S. W. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.89 · Cited by 62
Colman, E. G., Szarfman, A., Wyeth, J., Mosholder, A. D., Jillapalli, D., Levine, J. G., & Avigan, M. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1643 · Cited by 61
The Need for Definitions in Pharmacovigilance
Lindquist, M. (2007) · Drug Safety · doi:10.2165/00002018-200730100-00001 · Cited by 58
[French pharmacovigilance database system: examples of utilisation].
Moore, N. D., Noblet, C., Kreft-Jaïs, C., Lagier, G., Ollagnier, M., & Jl, I. (1995) · PubMed · Cited by 57
McAdams‐DeMarco, M., Governale, L. A., Swartz, L., Hammad, T. A., & Pan, G. J. D. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1633 · Cited by 56
Giezen, T. J., Mantel-Teeuwisse, A. K., Meyboom, R. H. B., Straus, S. M. J. M., Leufkens, H. G. M., & Egberts, T. C. G. (2010) · Drug Safety · doi:10.2165/11538330-000000000-00000 · Cited by 54
An Evaluation of Three Signal-Detection Algorithms Using a Highly Inclusive Reference Event Database
Hochberg, A. M., Hauben, M., Pearson, R. K., O’Hara, D. J., Reisinger, S. J., Goldsmith, D. I., Gould, A. L., & Madigan, D. (2009) · Drug Safety · doi:10.2165/00002018-200932060-00007 · Cited by 47
Sakaeda, T., Kadoyama, K., Yabuuchi, H., Niijima, S., Seki, K., Shiraishi, Y., & Okuno, Y. (2011) · International Journal of Medical Sciences · doi:10.7150/ijms.8.332 · Cited by 43
Self-citationWhen to publish measures of disproportionality derived from spontaneous reporting databases?
de Boer, A. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04087.x · Cited by 41
The statin wars: why AstraZeneca must retreat
Lancet, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14669-7 · Cited by 41
Gibbons, R. D., Segawa, E., Karabatsos, G., Amatya, A. K., Bhaumik, D. K., Brown, C. H., Kapur, K., Marcus, S. M., Hur, K., & Mann, J. J. (2008) · Statistics in Medicine · doi:10.1002/sim.3241 · Cited by 38
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones
Motola, D., Piccinni, C. P., Biagi, C., Raschi, E., Marra, A. R., Marchesini, G., & Poluzzi, E. (2012) · Drug Safety · doi:10.2165/11596510-000000000-00000 · Cited by 37
Hauben, M., & Reich, L. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0951-4 · Cited by 36
Drug‐induced gingival overgrowth: a study in the F rench P harmacovigilance D atabase
Bondon‐Guitton, E., Bagheri, H., & Montastruc, J. (2012) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2012.01878.x · Cited by 36
Tamura, T., Sakaeda, T., Kadoyama, K., & Okuno, Y. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.4549 · Cited by 35
Self-citationTime-to-Signal Comparison for Drug Safety Data-Mining Algorithms vs. Traditional Signaling Criteria
Hochberg, A., & Hauben, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.26 · Cited by 34
Reporting Patterns Indicative of Adverse Drug Interactions
Strandell, J., Caster, O., Bate, A., Norén, G. N., & Edwards, I. R. (2011) · Drug Safety · doi:10.2165/11586990-000000000-00000 · Cited by 34
de Jong, H. J. I., Saldi, S. R. F., Klungel, O. H., Vandebriel, R. J., Souverein, P. C., Meyboom, R. H. B., Passier, A., Loveren, H. V., & Tervaert, J. W. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041289 · Cited by 32
Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy
Knudsen, J. F., Sokol, G. H., & Flowers, C. M. (2008) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.00943.x · Cited by 30
Drug-versus-Drug Adverse Event Rate Comparisons
Hochberg, A. M., Pearson, R. K., O’Hara, D. J., & Reisinger, S. J. (2009) · Drug Safety · doi:10.2165/00002018-200932020-00006 · Cited by 28
Prospective Data Mining of Six Products in the US FDA Adverse Event Reporting System
Bailey, S., Singh, A., Azadian, R., Huber, P., & Blum, M. (2010) · Drug Safety · doi:10.2165/11319000-000000000-00000 · Cited by 25
Cetuximab infusion reactions: French pharmacovigilance database analysis
Grandvuillemin, A., Dautriche, A., Miremont‐Salamé, G., Fourrier‐Réglat, A., & Sgro, C. (2012) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155212457965 · Cited by 24
Sommet, A., Grolleau, S., Bagheri, H., Lapeyre‐Mestre, M., & Montastruc, J. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0497-3 · Cited by 18
Du, D., Goldsmith, J. V., Aikin, K. J., Encinosa, W. E., & Nardinelli, C. (2012) · Health Affairs · doi:10.1377/hlthaff.2010.1004 · Cited by 16
Safety Alert for Fentanyl Buccal Tablets
Administration, U. S. F. A. D. (2008) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360280801989401 · Cited by 16
A pre-marketing ALT signal predicts post-marketing liver safety
Moylan, C. A., Suzuki, A., Papay, J. I., Yuen, N., Ames, M. H., & Hunt, C. M. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.05.016 · Cited by 15
Chen, Y., Guo, J. J., Steinbuch, M., Lin, X. S., Buncher, C. R., & Patel, N. C. (2008) · The HKU Scholars Hub (University of Hong Kong) · doi:10.2165/1317117-200822060-00006 · Cited by 15
Ehrenpreis, E. D., Sifuentes, H., Ehrenpreis, J. E., Smith, Z. L., & Marshall, M. L. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.650165 · Cited by 7
Cited by
AI in Health: State of the Art, Challenges, and Future Directions
Wang, F., & Preininger, A. (2019) · Yearbook of Medical Informatics · doi:10.1055/s-0039-1677908 · Cited by 398
Artificial Intelligence for Drug Toxicity and Safety
Basile, A. O., Yahi, A., & Tatonetti, N. P. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.005 · Cited by 363
Noguchi, Y., Tachi, T., & Teramachi, H. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab347 · Cited by 285
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000510703 · Cited by 134
Outsider Oversight: Designing a Third Party Audit Ecosystem for AI Governance
Raji, I. D., Xu, P., Honigsberg, C., & Ho, D. (2022) · Proceedings of the 2022 AAAI/ACM Conference on AI, Ethics, and Society · doi:10.1145/3514094.3534181 · Cited by 209
Metadata
- Authors
- Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y.
- Venue
- International Journal of Medical Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2013
- Volume
- 10
- Issue
- 7
- Pages
- 796-803
- ISSN
- 1449-1907 (ISSN-L)
- OpenAlex
- W2113514677
- Cited by
- 1,048
- References
- 76
- FWCI
- 26.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.